FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Powell Andrew Kenneth William						2. Issuer Name and Ticker or Trading Symbol Aclaris Therapeutics, Inc. [ACRS] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)														
1 OWCH I MILLIEW INCHINEUT VVIIII and					⊢	•								X Directo	r		10% Ov	/ner		
(Last)	(F	irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/01/2023								Officer below)	(give title		Other (s below)	pecify		
C/O ACLARIS THERAPEUTICS, INC. 640 LEE ROAD, SUITE 200				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)							
														X Form filed by One Reporting Person						
(Street) WAYNE PA 19087					Form filed by More than One Reporting Person											ting				
					– lRu	ıle	10b5-	·1(c)	Transa	acti	on Indi	cation								
(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.															
		Tal	ole I - Nor	n-Deri	vative	Se	curitie	s Acc	quired, I	Disp	osed o	f, or Be	neficial	ly Owned						
D D			Date	saction /Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)		ed (A) or str. 3, 4 an	Beneficia Owned F	s ally following	Form: Direct (D) or Indirect		7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) 0 (D)	r Price	Reported Transact (Instr. 3 a	d tion(s)			(Instr. 4)		
Common Stock 06/0				06/0)2/2023	/2023 M 4,507 A		(1)	14,	14,363		D								
			Table II -								sed of, onvertib			Owned						
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date ecurity or Exercise (Mont		Transaction ate Execution I onth/Day/Year) Transaction Sa. Deeme Execution I if any (Month/Day			ansaction Derivative Securities Acquired (a or Dispose		Derivative Securities Acquired (A) or Disposed of (D) (Instr.		6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title ar Amount of Securitie Underlyir Derivative (Instr. 3 a			of s ng e Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	v			Date Exercisal:		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	лі(ъ)	5)			
Stock Option (Right to Buy)	\$8.7	06/01/2023			A		15,750		(2)(3)		05/31/2033	Common Stock	15,750	\$0.00	15,750		D			
Restricted Stock Units	(1)	06/01/2023			A		4,660		(2)(4)		(4)	Common Stock	4,660	\$0.00	4,660		D			
Restricted Stock Units	(1)	06/02/2023			М			4,507	(5)		(5)	Common Stock	4,507	\$0.00	0		D			

Explanation of Responses:

- $1. \ Each \ restricted \ stock \ unit \ represents \ a \ contingent \ right \ to \ receive \ one \ share \ of \ common \ stock \ of \ the \ issuer.$
- 2. This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy.
- 3. The shares subject to this option will vest in twelve equal monthly installments commencing July 1, 2023, subject to Reporting Person's continuous service through each such date.
- 4. The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date.
- 5. The shares underlying these restricted stock units vested on June 2, 2023.

Remarks:

/s/ Mark Ballantyne, Attorney-06/05/2023 in-Fact

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.